Targeted therapy with ixekizumab in pyoderma gangrenosum: A case series and a literature overview

Kao, Andrew S.; King, Andrew D.; Bardhi, Redina; Daveluy, Steven

doi:10.1016/j.jdcr.2023.05.002

Cited by 8 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other medications, including tacrolimus, azathioprine, minocycline, methotrexate, mycophenolate mofetil, sulfasalazine, and dapsone, have been used in combination or as monotherapy to treat this contentious condition. All of these medications have serious adverse effects when taken while pregnant [68].…”

Section: Discussionmentioning

confidence: 99%

Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis—Case Report and Literature Review

Matasariu,

Bujor,

Mihălceanu

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: The infrequent occurrence of pyoderma gangrenosum (PG) during pregnancy and in postpartum, with its subsequent diagnostic intricacies, caused us to present the following case. Methods: This article describes a rare case of PG in postpartum in a patient without any prior pathology and a short review of the literature, aiming to identify similar rare instances. Results: We conducted a literature review to ascertain the prevalence of postpartum pyoderma gangrenosum, and we identified a total of 41 cases. Conclusions: Our article underlines again the importance of interdisciplinary collaboration for the prompt identification and commencement of necessary therapeutic interventions in postpartum women afflicted by pyoderma gangrenosum.

show abstract

Section: Discussionmentioning

confidence: 99%

Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis—Case Report and Literature Review

Matasariu,

Bujor,

Mihălceanu

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…The treatment was discontinued at the end of 6 months as an adequate response to the treatment could not be obtained. There are case reports indicating that secukinumab, risankizumab, and ixekizumab are effective in resistant PG [29][30][31].…”

Section: Discussionmentioning

confidence: 99%

Analysis of clinical characteristics and factors affecting treatment responses in patients with pyoderma gangrenosum: A multicenter study of 239 patients

Erduran,

Adışen,

Hayran

et al. 2023

Preprint

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a chronic disease characterized by recalcitrant skin ulcers. We aimed to evaluate retrospectively the demographic, clinical characteristics, treatment data and factors affecting treatment responses of patients followed up with diagnosis of PG in 12 tertiary care centers from 8 different provinces in Turkey between the years 2012–2022. We included a total of 239 patients of whom 143 (59.8%) were female and 96 (40.2%) were male, with an average age of 54.2 ± 17.4 years. At least one comorbidity associated with PG was found in 51.5% of our patients. The most common comorbidities were inflammatory arthritis (18.8%) and inflammatory bowel disease (IBD) (15.9%). The most common treatment was systemic steroids (75.7%). Among these patients 50.8% used systemic steroids as the sole systemic agent, while 49.2% used at least one adjuvant immunosuppressive agent. The general characteristics of our patients who responded well to systemic steroid treatment were those with a late onset of disease, shorter disease duration, fewer lesions, single region involvement, negative wound culture results, negative pathergy, and those without inflammatory arthritis and IBD (all p < 0.05). Biological agents were used in 18.4% of our patients in our study. The general characteristics of the patients who switched to biologics as a second or third line treatment are those with early disease onset, younger patients, males, those with autoinflammatory diseases, those with IBD and hidradenitis suppurativa and pathergy positive ones (all p < 0.05). Our study had compelling data concerning two specific patient groups: Pathergy positivite and early onset (onset age < 30) PG groups. We think that investigation for accompanying autoinflammatory diseases at the time of diagnosis in these two groups is necessary and the patients in these two groups are more resistant to treatment, necessitating more complicated treatments. We believe that the results of our multicenter study will contribute to the literature.

show abstract

“…Interestingly, Sadik et al [156] reported induction of PG, palmoplantar pustulosis, and sacroiliitis after switching from secukinumab to brodalumab in plaque psoriasis patients. Kao et al [150,157] documented effective treatment of PG lesions in four patients after ixekizumab therapy. Nonetheless, there is a case report of PG manifestation in a patient undergoing ixekizumab treatment [158].…”

Section: Il-1 Antagonistsmentioning

confidence: 99%

“…IL-17 Inhibitors IL-17 inhibitors are a group of novel biological drugs that inhibit the activity of IL-17. The available literature describes the effects of treatment with three representatives of this group (secukinumab, ixekizumab, and brodalumab) [149][150][151]. The reports regarding the use of this group of biologic drugs and PG is ambiguous.…”

Section: Il-1 Antagonistsmentioning

confidence: 99%

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

Łyko,

Ryguła,

Kowalski

et al. 2024

IJMS

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is an uncommon inflammatory dermatological disorder characterized by painful ulcers that quickly spread peripherally. The pathophysiology of PG is not fully understood; however, it is most commonly considered a disease in the spectrum of neutrophilic dermatoses. The treatment of PG remains challenging due to the lack of generally accepted therapeutic guidelines. Existing therapeutic methods focus on limiting inflammation through the use of immunosuppressive and immunomodulatory therapies. Recently, several reports have indicated the successful use of biologic drugs and small molecules administered for coexisting diseases, resulting in ulcer healing. In this review, we summarize the discoveries regarding the pathophysiology of PG and present treatment options to raise awareness and improve the management of this rare entity.

show abstract

Targeted therapy with ixekizumab in pyoderma gangrenosum: A case series and a literature overview

Cited by 8 publications

References 15 publications

Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis—Case Report and Literature Review

Pyoderma Gangrenosum, a Challenging Postpartum Diagnosis—Case Report and Literature Review

Analysis of clinical characteristics and factors affecting treatment responses in patients with pyoderma gangrenosum: A multicenter study of 239 patients

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

Contact Info

Product

Resources

About